Cover Image
Market Research Report
Product code 
1070545

Orphan Drugs Market by Disease Type (Oncological Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, and Other Rare Diseases): Global Opportunity Analysis and Industry Forecast, 2021-2030

Published: | Allied Market Research | 356 Pages | Delivery time: 2-3 business days

Price

Back to Top
Orphan Drugs Market by Disease Type (Oncological Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, and Other Rare Diseases): Global Opportunity Analysis and Industry Forecast, 2021-2030
Published: February 24, 2022
Allied Market Research
Content info: 356 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global orphan drugs market was valued at $1,40,000.0 million in 2020 and is projected to reach $4,35,686.3 million by 2030 registering a CAGR of 11.8% from 2021 to 2030.

The pharmaceutical agents administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. Orphan drugs are used to treat rare (orphaned) diseases prevalent in a very small patient pool. Thus, the pharmaceutical industry takes little interest in their development. Moreover, their development requires high cost and the chances of returns on investment are comparatively less when compared to non-orphan drugs. These drugs treat different rare diseases, such as non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, and Duchenne muscular dystrophy, graft vs. host disease, and others.

The main factor that drives the growth of the orphan drugs market includes increase in prevalence of rare diseases. In addition, favorable government policies, and availability of market exclusivity for orphan drugs developers further supplement the global orphan drugs market growth.

Conversely, limited patient pool for clinical trials and product marketing, and high treatment costs per patient are expected to obstruct the growth of the market during the forecast years. On the other hand, high growth potential in untapped emerging economies, and rise in novel indications for known orphan drugs are expected to offer profitable opportunities for the growth of the market during the forecast period. The global orphan drugs market is segmented on the basis of disease type, and region to provide a detailed assessment of the market.

By disease type, it is categorized into oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurological diseases, and other rare diseases such as transplantation diseases, gastrointestinal diseases, dermatologic diseases, perinatal & congenital abnormalities, and others. Oncological diseases segment is further divided into acute myeloid leukemia (AML), pancreatic cancer, ovarian cancer, multiple myeloma, renal cell carcinoma, and others.

  • In addition, the metabolic diseases segment is again classified into hunter syndrome, Fabry disease, Gaucher disease, hypoparathyroidism, and others. Furthermore, hematologic & immunologic diseases segment is segmented into hereditary angioedema (HAE), hemophilia, and others. Moreover, neurological diseases segment is further segmented into Duchenne muscular dystrophy (DMD), Alzheimer's disease, Huntington's disease, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
  • The key market players profiled in the report include Abbvie Inc., Amgen Inc., Amryt Pharma Plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithkline PLC, Johnson & Johnson (Janssen Global Services, LLC), Novartis AG (Sandoz), Pfizer, Inc., and Sanofi S.A.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global orphan drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of orphan drugs used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

  • By Disease Type
    • Oncological Diseases
      • Acute Myeloid Leukemia (AML)
      • Pancreatic Cancer
      • Ovarian cancer
      • Multiple Myeloma
      • Renal Cell Carcinoma
      • Others
    • Metabolic Diseases
      • Hunter Syndrome
      • Fabry Disease
      • Gaucher Disease
      • Hypoparathyroidism
      • Others
    • Hematologic & Immunologic Diseases
      • Hereditary Angioedema (HAE)
      • Hemophilia
      • Others
    • Infectious Diseases
    • Neurologic Diseases
      • Duchenne Muscular Dystrophy
      • Alzheimer's Disease
      • Huntington's Disease
      • Others
    • Other Rare Diseases
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Australia
      • India
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Turkey
      • South Africa
      • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Abbvie Inc.
  • Amgen Inc.
  • Amryt Pharma Plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithkline PLC
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Sanofi S.A.
Product Code: LI_17204 / A00116

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Patent analysis, 2017-2022
    • 3.5.1.Patent analysis, world
    • 3.5.2.Patent analysis, by Indication
  • 3.6.Regulation
    • 3.6.1.U.S.
    • 3.6.2.Europe
    • 3.6.3.Japan
  • 3.7.Market dynamics
    • 3.7.1.Drivers
      • 3.7.1.1.Increase in prevalence of rare diseases
      • 3.7.1.2.Favorable government policies
      • 3.7.1.3.Availability of exclusivity for orphan drugs
    • 3.7.2.Restraints
      • 3.7.2.1.Limited patient pool for clinical trials and product marketing
      • 3.7.2.2.High treatment costs per patient
    • 3.7.3.Opportunity
      • 3.7.3.1.High growth potential in untapped emerging economies
      • 3.7.3.2.Use of orphan drugs for novel conditions/indications
    • 3.7.4.Impact analysis
  • 3.8.COVID-19 Impact analysis on the orphan drugs market

CHAPTER 4:ORPHAN DRUGS MARKET, DISEASE TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Oncological diseases
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Market size and forecast, by type
    • 4.2.5.Acute Myeloid Leukemia (AML)
      • 4.2.5.1.Market size and forecast, by region
      • 4.2.5.2.Market analysis, by country
    • 4.2.6.Pancreatic Cancer
      • 4.2.6.1.Market size and forecast, by region
      • 4.2.6.2.Market analysis, by country
    • 4.2.7.Ovarian cancer
      • 4.2.7.1.Market size and forecast, by region
      • 4.2.7.2.Market analysis, by country
    • 4.2.8.Multiple Myeloma
      • 4.2.8.1.Market size and forecast, by region
      • 4.2.8.2.Market analysis, by country
    • 4.2.9.Renal Cell Carcinoma
      • 4.2.9.1.Market size and forecast, by region
      • 4.2.9.2.Market analysis, by country
    • 4.2.10.Others
      • 4.2.10.1.Market size and forecast, by region
      • 4.2.10.2.Market analysis, by country
  • 4.3.Metabolic diseases
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
    • 4.3.4.Market size and forecast, by type
    • 4.3.5.Hunter Syndrome
      • 4.3.5.1.Market size and forecast, by region
      • 4.3.5.2.Market analysis, by country
    • 4.3.6.Fabry Disease
      • 4.3.6.1.Market size and forecast, by region
      • 4.3.6.2.Market analysis, by country
    • 4.3.7.Gaucher Disease
      • 4.3.7.1.Market size and forecast, by region
      • 4.3.7.2.Market analysis, by country
    • 4.3.8.Hypoparathyroidism
      • 4.3.8.1.Market size and forecast, by region
      • 4.3.8.2.Market analysis, by country
    • 4.3.9.Others
      • 4.3.9.1.Market size and forecast, by region
      • 4.3.9.2.Market analysis, by country
  • 4.4.Hematologic & Immunologic diseases
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
    • 4.4.4.Market size and forecast, by type
    • 4.4.5.Hereditary Angioedema (HAE)
      • 4.4.5.1.Market size and forecast, by region
      • 4.4.5.2.Market analysis, by country
    • 4.4.6.Hemophilia
      • 4.4.6.1.Market size and forecast, by region
      • 4.4.6.2.Market analysis, by country
    • 4.4.7.Others
      • 4.4.7.1.Market size and forecast, by region
      • 4.4.7.2.Market analysis, by country
  • 4.5.Infectious diseases
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Neurological diseases
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
    • 4.6.4.Market size and forecast, by type
    • 4.6.5.Duchenne Muscular Dystrophy
      • 4.6.5.1.Market size and forecast, by region
      • 4.6.5.2.Market analysis, by country
    • 4.6.6.Alzheimer's Disease
      • 4.6.6.1.Market size and forecast, by region
      • 4.6.6.2.Market analysis, by country
    • 4.6.7.Huntington's Disease
      • 4.6.7.1.Market size and forecast, by region
      • 4.6.7.2.Market analysis, by country
    • 4.6.8.Others
      • 4.6.8.1.Market size and forecast, by region
      • 4.6.8.2.Market analysis, by country
  • 4.7.Other rare diseases
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country

CHAPTER 5:ORPHAN DRUGS MARKET, BY REGION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.North America
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by country
      • 5.2.2.1.U.S.
      • 5.2.2.1.1.U.S. orphan drugs market, by disease type
      • 5.2.2.1.1.1.U.S. orphan drugs market, by oncological diseases
      • 5.2.2.1.1.2.U.S. orphan drugs market, by metabolic diseases
      • 5.2.2.1.1.3.U.S. orphan drugs market, by hematology & immunology diseases
      • 5.2.2.1.1.4.U.S. orphan drugs market, by neurological diseases
      • 5.2.2.2.Canada
      • 5.2.2.2.1.Canada orphan drugs market, by disease type
      • 5.2.2.2.1.1.Canada orphan drugs market, by oncological diseases
      • 5.2.2.2.1.2.Canada orphan drugs market, by metabolic diseases
      • 5.2.2.2.1.3.Canada orphan drugs market, by hematology & immunology diseases
      • 5.2.2.2.1.4.Canada orphan drugs market, by neurological diseases
      • 5.2.2.3.Mexico
      • 5.2.2.3.1.Mexico orphan drugs market, by disease type
      • 5.2.2.3.1.1.Mexico orphan drugs market, by oncological diseases
      • 5.2.2.3.1.2.Mexico orphan drugs market, by metabolic diseases
      • 5.2.2.3.1.3.Mexico orphan drugs market, by hematology & immunology diseases
      • 5.2.2.3.1.4.Mexico orphan drugs market, by neurological diseases
    • 5.2.3.North America market size and forecast, by disease type
      • 5.2.3.1.North America orphan drugs market, by oncological diseases
      • 5.2.3.2.North America orphan drugs market, by metabolic diseases
      • 5.2.3.3.North America orphan drugs market, by hematology & immunology diseases
      • 5.2.3.4.North America orphan drugs market, by neurological diseases
  • 5.3.Europe
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by country
      • 5.3.2.1.Germany
      • 5.3.2.1.1.Germany orphan drugs market, by disease type
      • 5.3.2.1.1.1.Germany orphan drugs market, by oncological diseases
      • 5.3.2.1.1.2.Germany orphan drugs market, by metabolic diseases
      • 5.3.2.1.1.3.Germany orphan drugs market, by hematology & immunology diseases
      • 5.3.2.1.1.4.Germany orphan drugs market, by neurological diseases
      • 5.3.2.2.France
      • 5.3.2.2.1.France orphan drugs market, by disease type
      • 5.3.2.2.1.1.France orphan drugs market, by oncological diseases
      • 5.3.2.2.1.2.France orphan drugs market, by metabolic diseases
      • 5.3.2.2.1.3.France orphan drugs market, by hematology & immunology diseases
      • 5.3.2.2.1.4.France orphan drugs market, by neurological diseases
      • 5.3.2.3.UK
      • 5.3.2.3.1.UK orphan drugs market, by disease type
      • 5.3.2.3.1.1.UK orphan drugs market, by oncological diseases
      • 5.3.2.3.1.2.UK orphan drugs market, by metabolic diseases
      • 5.3.2.3.1.3.UK orphan drugs market, by hematology & immunology diseases
      • 5.3.2.3.1.4.UK orphan drugs market, by neurological diseases
      • 5.3.2.4.Italy
      • 5.3.2.4.1.Italy orphan drugs market, by disease type
      • 5.3.2.4.1.1.Italy orphan drugs market, by oncological diseases
      • 5.3.2.4.1.2.Italy orphan drugs market, by metabolic diseases
      • 5.3.2.4.1.3.Italy orphan drugs market, by hematology & immunology diseases
      • 5.3.2.4.1.4.Italy orphan drugs market, by neurological diseases
      • 5.3.2.5.Spain
      • 5.3.2.5.1.Spain orphan drugs market, by disease type
      • 5.3.2.5.1.1.Spain orphan drugs market, by oncological diseases
      • 5.3.2.5.1.2.Spain orphan drugs market, by metabolic diseases
      • 5.3.2.5.1.3.Spain orphan drugs market, by hematology & immunology diseases
      • 5.3.2.5.1.4.Spain orphan drugs market, by neurological diseases
      • 5.3.2.6.Rest of Europe
      • 5.3.2.6.1.Rest of Europe orphan drugs market, by disease type
      • 5.3.2.6.1.1.Rest of Europe orphan drugs market, by oncological diseases
      • 5.3.2.6.1.2.Rest of Europe orphan drugs market, by metabolic diseases
      • 5.3.2.6.1.3.Rest of Europe orphan drugs market, by hematology & immunology diseases
      • 5.3.2.6.1.4.Rest of Europe orphan drugs market, by neurological diseases
    • 5.3.3.Europe market size and forecast, by disease type
      • 5.3.3.1.Europe orphan drugs market, by oncological diseases
      • 5.3.3.2.Europe orphan drugs market, by metabolic diseases
      • 5.3.3.3.Europe orphan drugs market, by hematology & immunology diseases
      • 5.3.3.4.Europe orphan drugs market, by neurological diseases
  • 5.4.Asia-Pacific
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by country
      • 5.4.2.1.Japan
      • 5.4.2.1.1.Japan orphan drugs market, by disease type
      • 5.4.2.1.1.1.Japan orphan drugs market, by oncological diseases
      • 5.4.2.1.1.2.Japan orphan drugs market, by metabolic diseases
      • 5.4.2.1.1.3.Japan orphan drugs market, by hematology & immunology diseases
      • 5.4.2.1.1.4.Japan orphan drugs market, by neurological diseases
      • 5.4.2.2.China
      • 5.4.2.2.1.China orphan drugs market, by disease type
      • 5.4.2.2.1.1.China orphan drugs market, by oncological diseases
      • 5.4.2.2.1.2.China orphan drugs market, by metabolic diseases
      • 5.4.2.2.1.3.China orphan drugs market, by hematology & immunology diseases
      • 5.4.2.2.1.4.China orphan drugs market, by neurological diseases
      • 5.4.2.3.Australia
      • 5.4.2.3.1.Australia orphan drugs market, by disease type
      • 5.4.2.3.1.1.Australia orphan drugs market, by oncological diseases
      • 5.4.2.3.1.2.Australia orphan drugs market, by metabolic diseases
      • 5.4.2.3.1.3.Australia orphan drugs market, by hematology & immunology diseases
      • 5.4.2.3.1.4.Australia orphan drugs market, by neurological diseases
      • 5.4.2.4.India
      • 5.4.2.4.1.India orphan drugs market, by disease type
      • 5.4.2.4.1.1.India orphan drugs market, by oncological diseases
      • 5.4.2.4.1.2.India orphan drugs market, by Metabolic diseases
      • 5.4.2.4.1.3.India orphan drugs market, by hematology & immunology diseases
      • 5.4.2.4.1.4.India orphan drugs market, by neurological diseases
      • 5.4.2.5.Rest of Asia-Pacific
      • 5.4.2.5.1.Rest of Asia-Pacific orphan drugs market, by disease type
      • 5.4.2.5.1.1.Rest of Asia-Pacific orphan drugs market, by oncological diseases
      • 5.4.2.5.1.2.Rest of Asia-Pacific orphan drugs market, by Metabolic diseases
      • 5.4.2.5.1.3.Rest of Asia-Pacific orphan drugs market, by hematology & immunology diseases
      • 5.4.2.5.1.4.Rest of Asia-Pacific orphan drugs market, by neurological diseases
    • 5.4.3.Asia-Pacific market size and forecast, by disease type
      • 5.4.3.1.Asia-Pacific orphan drugs market, by oncological diseases
      • 5.4.3.2.Asia-Pacific orphan drugs market, by metabolic diseases
      • 5.4.3.3.Asia-Pacific orphan drugs market, by hematology & immunology diseases
      • 5.4.3.4.Asia-Pacific orphan drugs market, by neurological diseases
  • 5.5.LAMEA
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by country
      • 5.5.2.1.Brazil
      • 5.5.2.1.1.Brazil orphan drugs market, by disease type
      • 5.5.2.1.1.1.Brazil orphan drugs market, by oncological diseases
      • 5.5.2.1.1.2.Brazil orphan drugs market, by Metabolic diseases
      • 5.5.2.1.1.3.Brazil orphan drugs market, by hematology & immunology diseases
      • 5.5.2.1.1.4.Brazil orphan drugs market, by neurological diseases
      • 5.5.2.2.Turkey
      • 5.5.2.2.1.Turkey orphan drugs market, by disease type
      • 5.5.2.2.1.1.Turkey orphan drugs market, by oncological diseases
      • 5.5.2.2.1.2.Turkey orphan drugs market, by metabolic diseases
      • 5.5.2.2.1.3.Turkey orphan drugs market, by hematology & immunology diseases
      • 5.5.2.2.1.4.Turkey orphan drugs market, by neurological diseases
      • 5.5.2.3.South Africa
      • 5.5.2.3.1.South Africa orphan drugs market, by disease type
      • 5.5.2.3.1.1.South Africa orphan drugs market, by oncological diseases
      • 5.5.2.3.1.2.South Africa orphan drugs market, by metabolic diseases
      • 5.5.2.3.1.3.South Africa orphan drugs market, by hematology & immunology diseases
      • 5.5.2.3.1.4.South Africa orphan drugs market, by neurological diseases
      • 5.5.2.4.Rest of LAMEA
      • 5.5.2.4.1.Rest of LAMEA orphan drugs market, by disease type
      • 5.5.2.4.1.1.Rest of LAMEA orphan drugs market, by oncological diseases
      • 5.5.2.4.1.2.Rest of LAMEA orphan drugs market, by metabolic diseases
      • 5.5.2.4.1.3.Rest of LAMEA orphan drugs market, by hematology & immunology diseases
      • 5.5.2.4.1.4.Rest of LAMEA orphan drugs market, by neurological diseases
    • 5.5.3.LAMEA market size and forecast, by disease type
      • 5.5.3.1.LAMEA orphan drugs market, by oncological diseases
      • 5.5.3.2.LAMEA orphan drugs market, by Metabolic diseases
      • 5.5.3.3.LAMEA orphan drugs market, by hematology & immunology diseases
      • 5.5.3.4.LAMEA orphan drugs market, by neurological diseases

CHAPTER 6:COMPANY PROFILES

  • 6.1.ABBVIE INC.
    • 6.1.1.Company overview
    • 6.1.2.Company snapshot
    • 6.1.3.Operating business segments
    • 6.1.4.Product portfolio
    • 6.1.5.Business performance
    • 6.1.6.Key strategic moves and developments
  • 6.2.AMGEN INC.
    • 6.2.1.Company overview
    • 6.2.2.Company snapshot
    • 6.2.3.Operating business segments
    • 6.2.4.Product portfolio
    • 6.2.5.Business performance
    • 6.2.6.Key strategic moves and developments
  • 6.3.AMRYT PHARMA PLC.
    • 6.3.1.Company overview
    • 6.3.2.Company snapshot
    • 6.3.3.Operating business segments
    • 6.3.4.Product Portfolio
    • 6.3.5.Business performance
    • 6.3.6.Key strategic moves and developments
  • 6.4.BRISTOL-MYERS SQUIBB COMPANY
    • 6.4.1.Company overview
    • 6.4.2.Company snapshot
    • 6.4.3.Operating business segments
    • 6.4.4.Product Portfolio
    • 6.4.5.Business performance
    • 6.4.6.Key strategic moves and developments
  • 6.5.F. HOFFMANN-LA ROCHE LTD.
    • 6.5.1.Company overview
    • 6.5.2.Company snapshot
    • 6.5.3.Operating business segments
    • 6.5.4.Product portfolio
    • 6.5.5.Business performance.
    • 6.5.6.Key strategic moves and developments
  • 6.6.GLAXOSMITHKLINE PLC (GSK)
    • 6.6.1.Company overview
    • 6.6.2.Company snapshot
    • 6.6.3.Operating business segments
    • 6.6.4.Product portfolio
    • 6.6.5.Business performance
  • 6.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
    • 6.7.1.Company overview
    • 6.7.2.Company snapshot
    • 6.7.3.Operating business segments
    • 6.7.4.Product portfolio
    • 6.7.5.Business performance
    • 6.7.6.Key strategic moves and developments
  • 6.8.NOVARTIS INTERNATIONAL AG (SANDOZ)
    • 6.8.1.Company overview
    • 6.8.2.Company snapshot
    • 6.8.3.Operating business segments
    • 6.8.4.Product portfolio
    • 6.8.5.Business performance
    • 6.8.6.Key strategic moves and developments
  • 6.9.PFIZER INC.
    • 6.9.1.Company overview
    • 6.9.2.Company snapshot
    • 6.9.3.Operating business segments
    • 6.9.4.Product portfolio
    • 6.9.5.Business performance
    • 6.9.6.Key strategic moves and developments
  • 6.10.SANOFI S.A
    • 6.10.1.Company overview
    • 6.10.2.Company snapshot
    • 6.10.3.Operating business segments
    • 6.10.4.Product portfolio
    • 6.10.5.Business performance
    • 6.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 02.ORPHAN DRUGS MARKET FOR ONCOLOGICAL DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.ORPHAN DRUGS MARKET, FOR ONCOLOGICAL DISEASES, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 04.ORPHAN DRUGS MARKET FOR ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.ORPHAN DRUGS MARKET FOR PANCREATIC CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.ORPHAN DRUGS MARKET FOR OVARIAN CANCER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.ORPHAN DRUGS MARKET FOR MULTIPLE MYELOMA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.ORPHAN DRUGS MARKET FOR RENAL CELL CARCINOMA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.ORPHAN DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.ORPHAN DRUGS MARKET FOR METABOLIC DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.ORPHAN DRUGS MARKET, FOR METABOLLIC DISEASES, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 12.ORPHAN DRUGS MARKET FOR HUNTER SYNDROME, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.ORPHAN DRUGS MARKET FOR FABRY DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.ORPHAN DRUGS MARKET FOR GAUCHER DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.ORPHAN DRUGS MARKET FOR HYPOPARATHYROIDISM, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.ORPHAN DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.ORPHAN DRUGS MARKET FOR HEMATOLOGIC & IMMUNOLOGIC DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.ORPHAN DRUGS MARKET, FOR HEMATOLOGIC & IMMUNOLOGIC DISEASES, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 19.ORPHAN DRUGS MARKET FOR HEREDITARY ANGIOEDEMA (HAE), BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.ORPHAN DRUGS MARKET FOR HEMOPHILIA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 21.ORPHAN DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 22.ORPHAN DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 23.ORPHAN DRUGS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 24.ORPHAN DRUGS MARKET, FOR NEUROLOGICAL DISEASE, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 25.ORPHAN DRUGS MARKET FOR DUCHENNE MUSCULAR DYSTROPHY (DMD), BY REGION, 2020-2030 ($MILLION)
  • TABLE 26.ORPHAN DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 27.ORPHAN DRUGS MARKET FOR HUNTINGTON'S DISEASE (HD), BY REGION, 2020-2030 ($MILLION)
  • TABLE 28.ORPHAN DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 29.ORPHAN DRUGS MARKET FOR OTHER RARE DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 30.ORPHAN DRUGS MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 31.NORTH AMERICA ORPHAN DRUGS MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 32.U.S. ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 33.U.S. ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 34.U.S. ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 35.U.S. ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 36.U.S. ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030 ($MILLION)
  • TABLE 37.CANADA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 38.CANADA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 39.CANADA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 40.CANADA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 41.CANADA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES ($MILLION)
  • TABLE 42.MEXICO ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 43.MEXICO ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 44.MEXICO ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 45.MEXICO ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 46.MEXICO ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 47.NORTH AMERICA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 48.NORTH AMERICA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 49.NORTH AMERICA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 50.NORTH AMERICA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 51.NORTH AMERICA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 52.EUROPE ORPHAN DRUGS MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 53.GERMANY ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 54.GERMANY ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 55.GERMANY ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 56.GERMANY ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 57.GERMANY ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 58.FRANCE ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 59.FRANCE ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 60.FRANCE ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 61.FRANCE ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 62.FRANCE ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 63.UK ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 64.UK ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 65.UK ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 66.UK ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 67.UK ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 68.ITALY ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 69.ITALY ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 70.ITALY ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 71.ITALY ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 72.ITALY ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 73.SPAIN ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 74.SPAIN ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 75.SPAIN ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 76.SPAIN ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 77.SPAIN ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 78.REST OF EUROPE ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 79.REST OF EUROPE ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 80.REST OF EUROPE ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 81.REST OF EUROPE ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 82.REST OF ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 83.EUROPE ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 84.EUROPE ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 85.EUROPE ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 86.EUROPE ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 87.EUROPE ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 88.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 89.JAPAN ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 90.JAPAN ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 91.JAPAN ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 92.JAPAN ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 93.JAPAN ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 94.CHINA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 95.CHINA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 96.CHINA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 97.CHINA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 98.CHINA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 99.AUSTRALIA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 100.AUSTRALIA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 101.AUSTRALIA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 102.AUSTRALIA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 103.AUSTRALIA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 104.INDIA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 105.INDIA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 106.INDIA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 107.INDIA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 108.INDIA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 109.REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 110.REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 111.REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 112.REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 113.REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030 ($MILLION)
  • TABLE 114.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 115.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 116.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 117.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 118.ASIA-PACIFIC ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 119.LAMEA ORPHAN DRUGS MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 120.BRAZIL ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 121.BRAZIL ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 122.BRAZIL ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 123.BRAZIL ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 124.BRAZIL ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 125.TURKEY ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 126.TURKEY ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 127.TURKEY ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 128.TURKEY ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 129.TURKEY ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 130.SOUTH AFRICA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 131.SOUTH AFRICA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 132.SOUTH AFRICA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 133.SOUTH AFRICA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 134.SOUTH AFRICA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 135.REST OF LAMEA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 136.REST OF LAMEA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 137.REST OF LAMEA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 138.REST OF LAMEA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 139.REST OF ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030 ($MILLION)
  • TABLE 140.LAMEA ORPHAN DRUGS MARKET, BY DISEASE TYPE, 2020-2030($MILLION)
  • TABLE 141.LAMEA ORPHAN DRUGS MARKET, BY ONCOLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 142.LAMEA ORPHAN DRUGS MARKET, BY METABOLIC DISEASES, 2020-2030($MILLION)
  • TABLE 143.LAMEA ORPHAN DRUGS MARKET, BY HEMATOLOGY & IMMUNOLOGY DISEASES, 2020-2030($MILLION)
  • TABLE 144.LAMEA ORPHAN DRUGS MARKET, BY NEUROLOGICAL DISEASES, 2020-2030($MILLION)
  • TABLE 145.ABBVIE: COMPANY SNAPSHOT
  • TABLE 146.ABBVIE: OPERATING SEGMENT
  • TABLE 147.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 148.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149.AMGEN: COMPANY SNAPSHOT
  • TABLE 150.AMGEN: OPERATING SEGMENT
  • TABLE 151.AMGEN: PRODUCT PORTFOLIO
  • TABLE 152.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153.AMRYT PHARMA PLC.: COMPANY SNAPSHOT
  • TABLE 154.AMRYT PHARMA PLC.: PRODUCT PORTFOLIO
  • TABLE 155.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 156.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 157.ROCHE: COMPANY SNAPSHOT
  • TABLE 158.ROCHE: OPERATING SEGMENTS
  • TABLE 159.ROCHE: PRODUCT PORTFOLIO
  • TABLE 160.GSK: COMPANY SNAPSHOT
  • TABLE 161.GSK: OPERATING SEGMENTS
  • TABLE 162.GSK: PRODUCT PORTFOLIO
  • TABLE 163.J&J: COMPANY SNAPSHOT
  • TABLE 164.J&J: OPERATING SEGMENTS
  • TABLE 165.J&J: PRODUCT TYPE PORTFOLIO
  • TABLE 166.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 167.NOVARTIS: OPERATING SEGMENTS
  • TABLE 168.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 169.PFIZER: COMPANY SNAPSHOT
  • TABLE 170.PFIZER: PRODUCT PORTFOLIO
  • TABLE 171.SANOFI: COMPANY SNAPSHOT
  • TABLE 172.SANOFI: OPERATING SEGMENTS
  • TABLE 173.SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ORPHAN DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2022
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2022
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2022
  • FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.LOW THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.ORPHAN PRODUCT DESIGNATION BY DRUGS AND BIOLOGICS
  • FIGURE 13.PATENTS ANALYSIS, BY YEAR, 2017-2022
  • FIGURE 14.IMPACT ANALYSIS
  • FIGURE 15.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR ONCOLOGICAL DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OVARIAN CANCER, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR RENAL CELL CARCINOMA, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HUNTER SYNDROME, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR FABRY DISEASE, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR GAUCHER DISEASE, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HYPOPARATHYROIDISM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 27.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 28.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HEMATOLOGIC & IMMUNOLOGIC DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 29.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HEREDITARY ANGIOEDEMA (HAE), BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HEMOPHILIA, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 32.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 33.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR DUCHENNE MUSCULAR DYSTROPHY (DMD), BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 35.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 36.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR HUNTINGTON'S DISEASE (HD), BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 37.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 38.COMPARATIVE ANALYSIS OF ORPHAN DRUGS MARKET FOR OTHER RARE DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 39.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 41.AMGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.AMGEN: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 43.REVENUE, 2018-2020 ($MILLION)
  • FIGURE 44.AMRYT PHARMA PLC.: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 45.REVENUE, 2018-2020 ($MILLION)
  • FIGURE 46.BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 47.ROCHE: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 48.ROCHE: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 49.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 51.GSK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 52.J&J: REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53.J&J: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 54.J&J: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55.NOVARTIS: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 56.NOVARTIS: REVENUE SHARE BY SEGMENT, 2021
  • FIGURE 57.NOVARTIS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 59.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 60.SANOFI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 61.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 62.SANOFI: REVENUE SHARE BY REGION, 2020 (%)